Plott Ronald Todd purchased $10K of PHIO
Plott Ronald Todd purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at an average of $1.04 ($1.03–$1.04) across 2 trades over 2026-09-28 to 2026-09-29.
How this was made
The 30-second read
Why it matters
The director's purchase is a minor bullish signal but unlikely to affect price materially.
Market read
Limited relevance; primarily of interest to shareholders tracking insider activity.
What to watch
Potential upcoming clinical data or regulatory events not disclosed in the filing.
Background
SEC Form 4 filing discloses insider transactions; this is the first public report of this purchase.
Ticker impact
Director Plott Ronald Todd bought 10,000 shares of PHIO for $10,350, increasing his stake to 42,000 shares.
minimal upward pressure as the market may view the purchase as a positive signal
The transaction size ($10k) is trivial and unlikely to move the stock materially; however, insider buying can be a mild bullish cue.
Market effects
None significant; insider activity does not affect the broader biotech sector.
No regional impact.
Low; limited to PHIO investors.
Counterpoint
The purchase may be routine portfolio rebalancing rather than a strong endorsement.
Key entities
- CompanyPhio Pharmaceuticals Corp.
Biotech company listed on NASDAQ under ticker PHIO.
- PersonPlott Ronald Todd
Director of Phio Pharmaceuticals who made the purchase.
